

Roger J. Pomerantz, M.D., F.A.C.P.
Global Therapeutic Area Head, Infectious Disease Research & Development
Johnson & Johnson Pharmaceuticals Group

Dr. Roger J. Pomerantz is global therapeutic area head for infectious disease, with end-to-end research and development responsibility in the category. Pomerantz joined Johnson & Johnson in 2005 as the President of Tibotec Pharmaceuticals, Inc., a virology and infectious diseases R&D subsidiary of Johnson & Johnson.

Since Pomerantz joined Johnson & Johnson, the company's affiliates have launched PREZISTA, the first true second generation anti-HIV protease inhibitor (PI), and INTELENCE, the first second generation anti-HIV non-nucleoside reverse transcriptase inhibitor, within 18 months of each other, with approvals by numerous regulatory authorities worldwide. The company has also completed collaboration agreements with Vertex Pharmaceuticals, Inc. to co-develop and co-market Telaprevir, potentially the initial anti-hepatitis C protease inhibitor, and with Medivir Pharmaceuticals, Inc. to co-discover and then co-develop several key anti-HCV, HIV and hepatitis B (HBV) inhibitors. Over this time period and under his leadership, the company has also progressed six new drugs to treat HIV from early to full development.

Pomerantz received his B.A. in Biochemistry at the Johns Hopkins University (1978) and his M.D. at the Johns Hopkins School of Medicine (1982). He completed his Internal Medicine internship and residency training, and his subspecialty clinical and research training in Infectious Diseases and Virology at the Massachusetts General Hospital (M.G.H.) of the Harvard Medical School (1982 -1988), and was selected and served as the Chief Medical Resident at M.G.H (1988). His post-doctoral research training in Molecular Retrovirology was obtained at the Harvard Medical School and the Whitehead Institute of the Massachusetts Institute of Technology.

Pomerantz is board certified in both Internal Medicine and Infectious Diseases. He was Professor of Medicine, Biochemistry and Molecular Pharmacology, Chief of Infectious Diseases, and the Founding Director and Chair of the Institute for Human Virology and Biodefense at the Thomas Jefferson University and Medical School in Philadelphia between 1990 and 2005, and he has published over 300 peer-reviewed articles in the scientific literature and presented over 200 invited lectures, nationally and internationally, concentrating on pathogenic human viruses. He has been awarded significant numbers of National Institutes of Health (N.I.H.) grants and was continuously funded by the N.I.H. over several decades.

Pomerantz has served as an invited full-time member and then as the Chairman of the Antiviral Advisory Panel for the U.S. Food and Drug Administration, and on numerous invited N.I.H. advisory commissions, panels and committees. He is a Fellow of the American Association of Physicians, the American Society of Clinical Investigation, the American College of Physicians, and the Infectious Diseases Society of America, and received the President's Award of the International Society of Neurovirology. He is also a member of the Board of Trustees and the Board of Advisors of the Johns Hopkins Business School.